MCRB
Price
$1.12
Change
-$0.01 (-0.88%)
Updated
Nov 29, 6:59 PM EST
98 days until earnings call
MDGL
Price
$197.36
Change
+$6.42 (+3.36%)
Updated
Nov 29, 6:59 PM EST
85 days until earnings call
Ad is loading...

Compare predictions MCRB vs MDGL

Header iconMCRB vs MDGL Comparison
Open Charts MCRB vs MDGLBanner chart's image
Seres Therapeutics
Price$1.12
Change-$0.01 (-0.88%)
Volume$1.52M
CapitalizationN/A
Madrigal Pharmaceuticals
Price$197.36
Change+$6.42 (+3.36%)
Volume$155.95K
CapitalizationN/A
View a ticker or compare two or three
MCRB vs MDGL Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MCRB vs. MDGL commentary
Nov 29, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MCRB is a Buy and MDGL is a Buy.

COMPARISON
Comparison
Nov 29, 2023
Stock price -- (MCRB: $1.13 vs. MDGL: $190.94)
Brand notoriety: MCRB and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MCRB: 32% vs. MDGL: 51%
Market capitalization -- MCRB: $149.94M vs. MDGL: $3.9B
MCRB [@Biotechnology] is valued at $149.94M. MDGL’s [@Biotechnology] market capitalization is $3.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MCRB’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • MCRB’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than MCRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MCRB’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • MCRB’s TA Score: 5 bullish, 2 bearish.
  • MDGL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MCRB is a better buy in the short-term than MDGL.

Price Growth

MCRB (@Biotechnology) experienced а +8.13% price change this week, while MDGL (@Biotechnology) price change was +1.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.60%. For the same industry, the average monthly price growth was +37.65%, and the average quarterly price growth was +9.10%.

Reported Earning Dates

MCRB is expected to report earnings on Mar 06, 2024.

MDGL is expected to report earnings on Feb 22, 2024.

Industries' Descriptions

@Biotechnology (+4.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MCRB with price predictions.
OPEN
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($3.9B) has a higher market cap than MCRB($150M). MDGL YTD gains are higher at: -34.215 vs. MCRB (-79.821). MCRB has higher annual earnings (EBITDA): -124.01M vs. MDGL (-336.4M). MDGL has more cash in the bank: 232M vs. MCRB (170M). MDGL has less debt than MCRB: MDGL (117M) vs MCRB (212M). MCRB has higher revenues than MDGL: MCRB (127M) vs MDGL (0).
MCRBMDGLMCRB / MDGL
Capitalization150M3.9B4%
EBITDA-124.01M-336.4M37%
Gain YTD-79.821-34.215233%
P/E RatioN/AN/A-
Revenue127M0-
Total Cash170M232M73%
Total Debt212M117M181%
FUNDAMENTALS RATINGS
MCRB vs MDGL: Fundamental Ratings
MCRB
MDGL
OUTLOOK RATING
1..100
1528
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9335
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MCRB's Valuation (66) in the Biotechnology industry is in the same range as MDGL (96) in the Pharmaceuticals Other industry. This means that MCRB’s stock grew similarly to MDGL’s over the last 12 months.

MCRB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that MCRB’s stock grew similarly to MDGL’s over the last 12 months.

MCRB's SMR Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that MCRB’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for MCRB (93) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than MCRB’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as MCRB (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MCRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MCRBMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 14 days ago
88%
Bearish Trend 21 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CXE3.350.03
+0.90%
MFS High Income Municipal Trust
ECLN23.770.14
+0.61%
First Trust EIP Carbon Impact ETF
STLV25.67N/A
N/A
iShares Factors US Value Style ETF
XAR126.11-0.26
-0.21%
SPDR® S&P Aerospace & Defense ETF
QID11.87-0.06
-0.50%
ProShares UltraShort QQQ